慢性乙型肝炎治疗96周后未检测到TAF耐药

StephenW

Virginia Schad, PharmD
August 24, 2018
No Resistance to TAF Detected After 96 Weeks of Treatment in Chronic Hepatitis B
Share this content:

    facebook
    twitter
    linkedin
    google
    Email
    Print

No TAF-associated resistance substitutions associated with virologic breakthrough were found through 96 weeks of treatment. No TAF-associated resistance substitutions associated with virologic breakthrough were found through 96 weeks of treatment.

No difference in treatment response or efficacy was observed between tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) regardless of hepatitis B virus (HBV) genotype, including in patients with known resistance mutations at baseline, according to an integrated resistance analysis published in Antimicrobial Agents and Chemotherapy. Furthermore, no TAF-associated resistance substitutions associated with virologic breakthrough were found.

Researchers conducted 2 clinical trials (ClinicalTrials.gov Identifiers: NCT01940471, NCT01940341) during which 1298 patients with chronic hepatitis B (CHB) who were hepatitis e antigen positive or hepatitis e antigen negative were randomly assigned to receive either TAF (n=866) or TDF (n=432) for up to 144 weeks, followed by the option of an open-label TAF treatment up to week 384.

The patient population included in these trials represented global people with CHB and included patients who had not undergone treatment and those who had been treated and who were all infected with HBV genotypes A through D.

The researchers found that the proportion of patients achieving virus suppression (HBV DNA <69 IU/mL) was similar across treatment groups and that no substitutions associated with resistance to TAD or TDF were detected after 96 weeks.

Related Articles

    Transfusion-Transmitted Hepatitis B Virus: Minimizing the Risk
    Global Prevalence of Hepatitis B Virus Infection in 2016 Estimated
    BMI Linked to Hepatocellular Carcinoma Risk in Chronic Hepatitis B Virus

“Overall, this study demonstrates that TAF monotherapy achieved high levels of viral suppression over 96 weeks of treatment and that no resistance to TAF developed in patients with CHB,” concluded the authors.

Disclosure

This study was sponsored and financially supported by Gilead Sciences, Inc.
Reference

Cathcart AL, Chan HL-Y, Bhardwaj N, et al. No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis B [published online July 23, 2018]. Antimicrob Agents Chemother. doi: 10.1128/AAC.01064-18

StephenW

Virginia Schad，PharmD
2018年8月24日
慢性乙型肝炎治疗96周后未检测到TAF耐药
分享这个内容：

    Facebook的
    推特
    LinkedIn
    谷歌
    电子邮件
    打印

在96周的治疗中未发现与病毒学突破相关的TAF相关抗性替代。在96周的治疗中未发现与病毒学突破相关的TAF相关抗性替代。

根据发表的综合耐药性分析，无论乙型肝炎病毒（HBV）基因型如何，包括在基线已知耐药突变的患者，在替诺福韦艾拉酚胺（TAF）和替诺福韦地索普西富马酸盐（TDF）之间均未观察到治疗反应或疗效的差异。抗菌药物和化学疗法。此外，未发现与病毒学突破相关的TAF相关抗性替代。

研究人员进行了2项临床试验（ClinicalTrials.gov Identifiers：NCT01940471，NCT01940341），其中1298例乙型肝炎抗原阳性或肝炎e抗原阴性的慢性乙型肝炎（CHB）患者被随机分配接受TAF（n = 866）或TDF（n = 432）长达144周，随后选择开放标签的TAF治疗至384周。

这些试验中包括的患者群体代表全球CHB患者，包括未接受治疗的患者和接受过治疗且均感染HBV基因型A至D的患者。

研究人员发现，在治疗组中，实现病毒抑制（HBV DNA <69 IU / mL）的患者比例相似，并且在96周后未检测到与TAD或TDF抗性相关的替代。

相关文章

    输血传播的乙型肝炎病毒：最大限度地降低风险
    2016年全球乙型肝炎病毒感染率估计
    BMI与慢性乙型肝炎病毒的肝细胞癌风险相关

“总的来说，这项研究表明TAF单药治疗在96周的治疗中达到了高水平的病毒抑制，并且CHB患者对TAF没有产生耐药性，”作者总结道。

泄露

这项研究得到了Gilead Sciences，Inc。的资助和资助。
参考

Cathcart AL，Chan HL-Y，Bhardwaj N，et al。在慢性乙型肝炎患者中通过96周治疗未检测到对替诺福韦艾拉酚胺的耐药性[在线发表于2018年7月23日]。抗微生物剂Chemother。 doi：10.1128 / AAC.01064-18

Hepbest

嗯，我用TAF已经50多周啦。
So far So good